Indication

For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

Medicine details

Medicine name:
upadacitinib (Rinvoq)
SMC ID:
SMC2315
Pharmaceutical company
AbbVie Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
08 February 2021
SMC meeting date:
12 January 2021
Patient group submission deadline:
30 November 2020